Chi Sheng Pharma & Biotech (4111) reported revenue of NT$114.3 million for Oct 2026, +2.2% year on year and -2.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.2 billion (+5.2% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 67 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$114.3 million | +2.2% | -2.9% |
| Sep 2026 | NT$117.7 million | +5.8% | -0.4% |
| Aug 2026 | NT$118.2 million | +6.9% | -0.6% |
| Jul 2026 | NT$118.8 million | -1.2% | -3.2% |
| Jun 2026 | NT$122.8 million | -0.7% | -1.6% |
| May 2026 | NT$124.9 million | +0.3% | -2.0% |
| Apr 2026 | NT$127.5 million | +6.6% | +7.6% |
| Mar 2026 | NT$118.4 million | +5.1% | +12.8% |
| Feb 2026 | NT$105 million | +5.9% | -21.2% |
| Jan 2026 | NT$133.3 million | +23.7% | +11.3% |
| Dec 2025 | NT$119.7 million | -0.9% | +3.7% |
| Nov 2025 | NT$115.5 million | +6.3% | +3.2% |
| Oct 2025 | NT$111.8 million | +9.5% | +0.5% |
| Sep 2025 | NT$111.3 million | +19.0% | +0.6% |
| Aug 2025 | NT$110.6 million | +16.9% | -8.1% |
| Jul 2025 | NT$120.3 million | +25.1% | -2.7% |
| Jun 2025 | NT$123.6 million | +37.9% | -0.7% |
| May 2025 | NT$124.5 million | +23.9% | +4.1% |
| Apr 2025 | NT$119.6 million | +29.5% | +6.1% |
| Mar 2025 | NT$112.7 million | +31.6% | +13.7% |
| Feb 2025 | NT$99.1 million | +23.1% | -8.0% |
| Jan 2025 | NT$107.7 million | +6.7% | -10.8% |
| Dec 2024 | NT$120.7 million | +33.3% | +11.2% |
| Nov 2024 | NT$108.6 million | +20.9% | +6.3% |
| Oct 2024 | NT$102.2 million | +14.1% | +9.3% |
Jan–Oct 2026 cumulative: NT$1.2 billion (+5.2% YoY)
Other Biotech & Medical companies
Compare with peers: Chi Sheng Pharma & Biotech vs PEC / Chi Sheng Pharma & Biotech vs Lotus Pharm / Chi Sheng Pharma & Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16